Ipsen has submitted national marketing authorization variations for Somatuline Autogel 120mg injection to the drug regulatory authorities in 25 countries...
Ipsen announced that the FDA has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment...
Ipsen has announced that Somatuline Depot (lanreotide) Injection 120 mg was approved by the FDA for the treatment of adult...
Ipsen Biopharmaceuticals announced that Endocrine Practice has published Phase III clinical trial results examining the efficacy and safety of Somatuline...
Somatuline Autogel is indicated for: • The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values. • The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease (see section 5.1). • The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.